Scarica l'app Stockscreener
2.87
4.01%
-0.12
Dopo l'orario di chiusura:
3.10
0.23
+8.01%
Curevac N V Borsa (CVAC) Ultime notizie
CureVac (NASDAQ:CVAC) Shares Gap DownShould You Sell? - MarketBeat
CureVac (NASDAQ:CVAC) Trading 4.7% HigherHere's What Happened - MarketBeat
CureVac (NASDAQ:CVAC) Shares Down 5.5%What's Next? - MarketBeat
CureVac's SWOT analysis: mRNA pioneer's stock faces oncology pipeline hurdles - Investing.com
2 Small-Cap Stocks Set to Shine in a Bull Market - Benzinga
CUREVAC : Licensing deal boosts bank account - Marketscreener.com
Point72 Asset Management L.P. Sells 1,642,723 Shares of CureVac (NASDAQ:CVAC) - MarketBeat
CUREVAC : Positive one-off overshadows pipeline dryness - Marketscreener.com
mRNA Therapeutics Market Size to Hit USD 48.65 Billion by 2032 due to Advances in Cancer Treatment and Expanding mRNA Vaccine Applications | Research by SNS Insider - GlobeNewswire Inc.
CureVac NV (XTER:5CV) 50-Day SMA : €2.62 (As of Dec. 05, 2024) - GuruFocus.com
CureVac NV (STU:5CV) 5-Day RSI : 64.31 (As of Dec. 05, 2024) - GuruFocus.com
CureVac's SWOT analysis: mRNA pioneer's stock faces pivotal phase in oncology push - Investing.com
CureVac NV (LTS:0A9E) EBITDA per Share : $0.84 (TTM As of Sep. 2024) - GuruFocus.com
CureVac NV (LTS:0A9E) Profitability Rank : 3 (As of Sep. 2024) - GuruFocus.com
CureVac NV (LTS:0A9E) 3-Year FCF Growth Rate : 0.00% (As of Sep. 2024) - GuruFocus.com
CureVac NV (HAM:5CV) Cyclically Adjusted FCF per Share : €0.00 (As of Sep. 2024) - GuruFocus.com
CureVac NV (WBO:CVAC) Enterprise Value : €94.9 Mil (As of Dec. 01, 2024) - GuruFocus.com
CureVac NV (HAM:5CV) Altman Z-Score : 2.46 (As of Dec. 01, 2024) - GuruFocus.com
CureVac NV (STU:5CV) 3-Year FCF Growth Rate : 0.00% (As of Sep. 2024) - GuruFocus.com
CureVac NV (STU:5CV) Cyclically Adjusted Revenue per Share : €0.00 (As of Sep. 2024) - GuruFocus.com
CVAC (CureVac NV) 9-Day RSI : 62.66 (As of Nov. 30, 2024) - GuruFocus.com
CVACCureVac N.V. Ordinary Shares Latest Stock News & Market Updates - StockTitan
Analysts Are Optimistic We'll See A Profit From CureVac N.V. (NASDAQ:CVAC) - Simply Wall St
CureVac NV (STU:5CV) Total Assets : €854.2 Mil (As of Sep. 2024) - GuruFocus.com
CVAC (CureVac NV) Capex-to-Operating-Cash-Flow : 0.01 (As of Sep. 2024) - GuruFocus.com
Loss-Making CureVac N.V. (NASDAQ:CVAC) Set To Breakeven - Yahoo Finance
Is the Options Market Predicting a Spike in CureVac (CVAC) Stock? - MSN
CureVac NV (STU:5CV) Total Inventories : €0.5 Mil (As of Sep. 2024) - GuruFocus.com
CureVac NV (STU:5CV) 50-Day SMA : €2.65 (As of Nov. 21, 2024) - GuruFocus.com
CureVac NV (XTER:5CV) Float Percentage Of Total Shares Outs - GuruFocus.com
CureVac NV (STU:5CV) Retained Earnings : €-1,371.0 Mil (As of Sep. 2024) - GuruFocus.com
CureVac NV (FRA:5CV) Retained Earnings : €-1,371.0 Mil (As of Sep. 2024) - GuruFocus.com
CureVac NV (FRA:5CV) Free Cash Flow : €94.5 Mil (TTM As of Sep. 2024) - GuruFocus.com
CureVac NV (HAM:5CV) 3-Year Revenue Growth Rate : -16.20% (As of Sep. 2024) - GuruFocus.com
CureVac NV (FRA:5CV) EBITDA : €165.9 Mil (TTM As of Sep. 2024) - GuruFocus.com
CureVac’s stock soars on GSK’s $1.56 billion deal for its COVID-19 and flu vaccines - MSN
10 Best German Stocks To Buy Now - Insider Monkey
Is CureVac N.V. (CVAC) the Best German Stock to Buy Now? - Insider Monkey
CureVac NV (HAM:5CV) 3-Year Dividend Growth Rate : 0.00% (As of Jun. 2024) - GuruFocus.com
CVAC (CureVac NV) Short-Term Capital Lease Obligation : $5.46 Mil (As of Jun. 2024) - GuruFocus.com
mRNA Vaccine and Therapeutics Market 2024-2031: Global - openPR
CureVac NV earnings beat by €0.09, revenue topped estimates - Investing.com Canada
CureVac N.V. (NASDAQ:CVAC) Q3 2024 Earnings Call Transcript - Insider Monkey
CureVac NV (CVAC) Q3 2024 Earnings Call Highlights: Strong Financial Performance and Strategic ... - Yahoo Finance
CureVac Reports Significant Revenue Growth Amid Strategic Restructuring - TipRanks
CureVac Reports Surging Revenues and Profit Growth - TipRanks
CureVac on track with 30% workforce reduction - TipRanks
CureVac reports Q3 revenue EUR 493.9M vs. EUR 16.5M last year - TipRanks
CureVac sees cash runway into 2028 - TipRanks
CureVac Announces Financial Results for the Third Quarter and Fi - WICZ
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update - AccessWire
CureVac Surges on €400M GSK Deal, Reports 77% Success in Cancer Trial | CVAC Stock News - StockTitan
CureVac (CVAC) Set to Announce Earnings on Tuesday - MarketBeat
CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024 - AccessWire
CureVac NV (LTS:0A9E) EBITDA : $-275.09 Mil (TTM As of Jun. 2024) - GuruFocus.com
Alan Bash named president of Carvykti at Legend - BioCentury
CureVac appoints new CFO to drive growth By Investing.com - Investing.com Canada
CureVac’s Latest mRNA Advances Spark Investor Interest - TipRanks
CureVac Appoints Chief Financial Officer - Contract Pharma
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):